Lack of SDF-1 effect on TPO + IL-3–dependent proliferation of human CD34+ BM MNCs
| . | Suboptimal* stimulation by TPO + IL-3 . | Suboptimal stimulation by TPO + IL-3 + SDF-1 . | Optimal*stimulation by TPO + IL-3 . | Optimal stimulation by TPO + IL-3 + SDF-1 . |
|---|---|---|---|---|
| Day 6 | 1.2 ± 0.7 | 1.2 ± 0.8 | 2.6 ± 0.5 | 2.7 ± 0.7 |
| Day 11 | 3.6 ± 1.9 | 3.5 ± 2.2 | 6.8 ± 2.8 | 6.1 ± 3.5 |
| . | Suboptimal* stimulation by TPO + IL-3 . | Suboptimal stimulation by TPO + IL-3 + SDF-1 . | Optimal*stimulation by TPO + IL-3 . | Optimal stimulation by TPO + IL-3 + SDF-1 . |
|---|---|---|---|---|
| Day 6 | 1.2 ± 0.7 | 1.2 ± 0.8 | 2.6 ± 0.5 | 2.7 ± 0.7 |
| Day 11 | 3.6 ± 1.9 | 3.5 ± 2.2 | 6.8 ± 2.8 | 6.1 ± 3.5 |
Each data entry consists of data from 3 different donors. Data shown represent mean ± 1 SD.
SDF-1 indicates stromal-derived factor 1; TPO, thrombopoietin; IL-3, interleukin-3; BM MNCs, bone marrow mononuclear cells.
CD34+ cells (104 cells/point) were ex vivo expanded toward megakaryoblasts in the presence of TPO + IL-3 at suboptimal doses (10 ng/mL + 5 U/mL) or optimal doses (50 ng/mL + 20 U/mL) in the presence or absence of SDF-1 (100 ng/mL).